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BACKGROUND
Among patients with acute myocardial infarction, cardiogenic shock, and multivessel 
coronary artery disease, the risk of a composite of death from any cause or severe renal 
failure leading to renal-replacement therapy at 30 days was found to be lower with 
percutaneous coronary intervention (PCI) of the culprit lesion only than with immedi-
ate multivessel PCI. We evaluated clinical outcomes at 1 year.
METHODS
We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate mul-
tivessel PCI. The results for the primary end point of death or renal-replacement 
therapy at 30 days have been reported previously. Prespecified secondary end points at 
1 year included death from any cause, recurrent myocardial infarction, repeat revascu-
larization, rehospitalization for congestive heart failure, the composite of death or 
recurrent infarction, and the composite of death, recurrent infarction, or rehospitaliza-
tion for heart failure.
RESULTS
As reported previously, at 30 days, the primary end point had occurred in 45.9% of the 
patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group 
(P = 0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-
lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group 
(relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent 
infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative 
risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent in-
farction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). 
Repeat revascularization occurred more frequently with culprit-lesion-only PCI than 
with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 
to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 
95% CI, 1.53 to 13.04).
CONCLUSIONS
Among patients with acute myocardial infarction and cardiogenic shock, the risk of 
death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI 
than with immediate multivessel PCI, and mortality did not differ significantly between 
the two groups at 1 year of follow-up. (Funded by the European Union Seventh Frame-
work Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549.)
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Early revascularization has been shown to reduce mortality among patients with acute myocardial infarction that is 
complicated by cardiogenic shock.1-3 Most patients 
with cardiogenic shock present with multivessel 
coronary artery disease,4 which is associated with 
higher mortality than single-vessel disease.5-7 For 
the treatment of patients with multivessel disease, 
current European guidelines for the management 
of acute ST-segment elevation myocardial infarc-
tion recommend immediate percutaneous coro-
nary intervention (PCI) of both culprit and non-
culprit lesions,8 and U.S. appropriate-use criteria 
consider immediate revascularization of both cul-
prit and nonculprit arteries during the same proce-
dure to be highly appropriate.9 However, the 30-day 
results of the Culprit Lesion Only PCI versus Multi-
vessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) 
trial10 showed that the risk of a composite of death 
from any cause or severe renal failure leading to 
renal-replacement therapy was lower with culprit-
lesion-only PCI than with immediate multivessel 
PCI, thus challenging the guideline recommenda-
tions. On the basis of these results, the European 
revascularization guidelines have now downgrad-
ed immediate multivessel PCI in cardiogenic shock 
to a class III B recommendation (i.e., a recommen-
dation that the procedure is not useful and may 
be harmful, according to evidence from a single 
randomized trial).11
In light of the short-term results of the CULPRIT-
SHOCK trial, the use of multivessel PCI in patients 
with cardiogenic shock is now controversial.12,13 
Although immediate multivessel PCI is associated 
with initial harm, the resulting complete revascu-
larization could lead to a benefit over the long term. 
This possibility is supported by pooled evidence 
from nonrandomized trials showing that the 
higher short-term mortality with multivessel PCI 
than with culprit-lesion-only PCI was not sustained 
after longer-term follow-up.14,15 Furthermore, a re-
cent registry study suggested that there was lower 
mortality at 1 year with multivessel PCI than with 
culprit-lesion-only PCI.16 Further data obtained 
during longer observation periods in randomized 
trials have been limited. Here, we report the 
1-year results of the CULPRIT-SHOCK trial.
Me thods
Trial Design and Oversight
The trial design and the short-term results have 
been published previously.4,10 In summary, the 
CULPRIT-SHOCK trial was an investigator-initi-
ated, multicenter, randomized, open-label, multi-
center trial that compared culprit-lesion-only PCI 
(with optional staged revascularization) with im-
mediate multivessel PCI in patients who had acute 
myocardial infarction that was complicated by 
cardiogenic shock. The protocol (available with 
the full text of this article at NEJM.org) was de-
signed by the principal investigator and was modi-
fied and approved by the steering committee4; it 
was also approved by regional and national eth-
ics review boards. The trial was registered at 
ClinicalTrials.gov 4 months after the enrollment 
of the first patient, as discussed in the Supple-
mentary Appendix (available at NEJM.org).
Trial funding was provided by the European 
Union Seventh Framework Program, the German 
Heart Research Foundation, and the German Car-
diac Society. Additional support was provided by 
the German Center for Cardiovascular Research. 
These institutions had no involvement in the con-
duct of the trial, as reported previously. Data were 
maintained and independent statistical analysis 
was performed by a coordinating research orga-
nization, Institut für Herzinfarktforschung (In-
stitute for Myocardial Infarction Research). The 
steering committee vouches for the accuracy and 
completeness of the data and for the fidelity of 
the trial to the protocol. The statistician vouches 
for the accuracy of the data analysis. The patient-
level data, analytic methods, and trial materials 
cannot be made available to other researchers, 
because the European Union contract and the 
consortium agreement of the trial do not allow 
data sharing.
Patients
Patients who had acute myocardial infarction 
that was complicated by cardiogenic shock, as 
described previously,10 were eligible for the trial 
if they met the following criteria: planned early 
revascularization by means of PCI, multivessel 
coronary artery disease (defined as at least two 
major vessels [≥2 mm diameter] with >70% ste-
nosis of the diameter), and an identifiable culprit 
lesion. Exclusion criteria were resuscitation for 
longer than 30 minutes, no intrinsic heart action, 
an assumed severe deficit in cerebral function with 
fixed dilated pupils, an indication for primary 
coronary-artery bypass grafting, single-vessel coro-
nary artery disease, a mechanical cause of car-
diogenic shock, the onset of shock more than 12 
hours before randomization, an age of more than 
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90 years, shock with a noncardiogenic cause, 
massive pulmonary embolism, known severe 
renal insufficiency (creatinine clearance, <30 ml 
per minute), and other severe concomitant dis-
ease associated with a life expectancy of less 
than 6 months. Written informed consent was 
obtained with the use of a prespecified process 
(see the Supplementary Appendix).4
Randomization, Treatment, and Follow-up
Patients underwent randomization immediately 
after diagnostic angiography. Randomization was 
performed centrally with the use of an Internet-
based program with randomly changing blocks 
of 4 or 6 and stratification according to center.
Patients were randomly assigned, in a 1:1 ra-
tio, to undergo either culprit-lesion-only PCI or 
immediate multivessel PCI. In all patients, the 
culprit lesion was treated first, with the use of 
standard PCI techniques and with the recom-
mended use of drug-eluting stents. In patients in 
the culprit-lesion-only PCI group, all other le-
sions were to be left untreated at the time of the 
initial procedure. Staged revascularization was 
recommended on the basis of the patient’s clini-
cal status and the presence of residual ischemia 
on objective testing. In patients in the multives-
sel PCI group, all additional lesions (major coro-
nary arteries with >70% stenosis of the diameter), 
including chronic total occlusions, were recom-
mended to be treated with PCI immediately after 
treatment of the culprit lesion. In each group, 
the advised maximum dose of contrast material 
was 300 ml.
The use of mechanical circulatory support 
was left to the discretion of the operator. If re-
nal-replacement therapy was deemed to be nec-
essary, the method, duration, and reason for ini-
tiation were documented.
Trial-specific follow-up assessments were per-
formed at 6 months and at 1 year by means of a 
structured telephone interview. Any potential end-
point event was verified in a review of original 
records. In addition, death registries were searched 
to identify or confirm all deaths.
End Points
The primary end point was a composite of death 
from any cause or severe renal failure leading to 
renal-replacement therapy within 30 days after 
randomization; results for this outcome have been 
reported previously.10 For the 1-year analysis, re-
sults are reported for the following prespecified 
secondary end points: death from any cause, 
renal-replacement therapy, recurrent myocardial 
infarction, repeat revascularization, and rehospi-
talization for congestive heart failure. In addi-
tion, results are reported for the composite of 
death or recurrent infarction and for the com-
posite of death, recurrent infarction, or rehospi-
talization for heart failure.
Safety end points included stroke and bleed-
ing, which was defined as bleeding of type 2, 3, 
or 5 on the Bleeding Academic Research Consor-
tium (BARC) scale (with type 2 indicating any 
overt, actionable sign of bleeding; type 3, bleed-
ing with a decrease in the hemoglobin level of 
>3 g per deciliter, any transfusion, cardiac tampon-
ade, or intracranial or ocular involvement; and type 
5, fatal bleeding).4,17 Quality of life was assessed 
with the European Quality of Life–5 Dimensions 
(EQ-5D) questionnaire (www.euroqol.org), in-
cluding a visual-analogue scale, at 6 months and 
at 1 year. As a post hoc exploratory analysis, the 
primary end point of a composite of death or 
renal-replacement therapy was assessed at 1 year. 
Definitions of all end points are provided in the 
Supplementary Appendix. All end-point events 
were adjudicated by a clinical end-points commit-
tee whose members were unaware of the group 
assignments.
Statistical Analysis
The sample-size calculation and the design for the 
30-day analysis have been described previously and 
are summarized in the Supplementary Appen-
dix.4,10 For the 1-year analysis, data were included 
for all the patients who had at least 30 days of 
follow-up. All analyses were performed according 
to the intention-to-treat principle. The 1-year 
event rates were the percentages of patients who 
had an event within 365 days after randomiza-
tion. Event rates were compared by chi-square 
tests. Robustness of results was evaluated in sen-
sitivity analyses performed in the per-protocol 
and as-treated populations. End points that did 
not include death from any cause as a compo-
nent were analyzed in all patients as well as in 
patients who survived. Kaplan–Meier curves are 
used to show event rates over time with classifi-
cation according to group assignment. We also 
performed a post hoc landmark analysis using a 
cutoff point of 30 days after randomization, with 
hazard ratios calculated separately for events that 
occurred within 30 days and those that occurred 
between 30 days and 1 year.
The New England Journal of Medicine 
Downloaded from nejm.org at E-Library Insel on January 21, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;18 nejm.org November 1, 20181702
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Data from the quality-of-life assessment were 
analyzed, with chi-square tests, in patients who 
survived. Values on the visual-analogue scale were 
compared with Mann–Whitney U tests. Predefined 
subgroup analyses for 1-year mortality were per-
formed, as described previously.10 The resulting 
relative risks and 95% confidence intervals are 
presented in a forest plot. The Breslow–Day test 
was used to analyze the interaction between group 
assignment and subgroup.
No adjustment for multiple comparisons was 
performed for any of the analyses. P values are 
not reported, since all analyses presented here 
are for secondary end points. All analyses were 
conducted with the use of SAS software, version 
9.4 (SAS Institute).
R esult s
Patients
In total, 1075 patients with cardiogenic shock were 
screened at 83 centers, and 706 patients (65.7%) 
were randomly assigned to undergo culprit-lesion-
only PCI (351 patients) or immediate multivessel 
PCI (355 patients) (Fig. 1). Full informed consent 
was obtained for 344 and 342 patients, respec-
tively. One patient was lost to follow-up within 
30 days, and one additional patient was lost to 
follow-up between 30 days and 1 year. Data on 
vital status were available at 1 year for 343 pa-
tients in the culprit-lesion-only PCI group and 
for 341 patients in the multivessel PCI group, 
exactly meeting the prespecified sample-size re-
quirement of 684 patients after withdrawals.
The characteristics of the patients at baseline 
and procedural characteristics, including medi-
cations at discharge, are shown in Table 1 and 
Table 2, respectively. Immediate crossover oc-
curred in 43 patients (12.5%) in the culprit-le-
sion-only PCI group and in 32 patients (9.4%) in 
the multivessel PCI group. Among patients who 
received stents, drug-eluting stents were used in 
93.6% of the patients in the culprit-lesion-only 
PCI group and in 95.1% in the multivessel PCI 
group. There was no significant difference be-
tween the two groups in the Thrombolysis in 
Myocardial Infarction grade for epicardial perfu-
sion before or after PCI of the culprit artery. The 
overall dose of contrast material was significantly 
greater and the duration of fluoroscopy was sig-
nificantly longer in the multivessel PCI group 
than the culprit-lesion-only PCI group.
Clinical End Points
As reported previously, at 30 days, the primary end 
point of a composite of death or renal-replacement 
therapy had occurred in 158 of 344 patients 
(45.9%) in the culprit-lesion-only PCI group and 
in 189 of 341 patients (55.4%) in the multivessel 
PCI group (relative risk, 0.83; 95% confidence 
interval [CI], 0.71 to 0.96; P = 0.01). At 1 year, 
mortality did not differ significantly between 
the culprit-lesion-only PCI group and the multi-
vessel PCI group; death from any cause had oc-
curred in 172 of 344 patients (50.0%) and 194 of 
341 patients (56.9%), respectively (relative risk, 
0.88; 95% CI, 0.76 to 1.01) (Table 3 and Fig. 2A). 
Death from cardiovascular causes had occurred 
in 159 patients (46.2%) in the culprit-lesion-only 
PCI group and in 180 patients (52.8%) in the 
multivessel PCI group (relative risk, 0.88; 95% 
CI, 0.75 to 1.02). (For details on causes of death 
at 1 year, see Table S1 in the Supplementary Ap-
pendix.)
A post hoc landmark analysis revealed a dif-
ference between the two groups in mortality 
within the first 30 days (relative risk, 0.84; 95% 
CI, 0.72 to 0.98), but mortality was similar in the 
two groups thereafter (relative risk, 1.08; 95% 
CI, 0.60 to 1.93) (Fig. 2B). Between 30 days and 
1 year, 23 patients (6.7%) died in the culprit-
lesion-only PCI group and 18 patients (5.3%) 
died in the multivessel PCI group. Results for 
mortality between baseline and 1 year in the 
intention-to-treat population were similar to re-
sults in the per-protocol population (relative 
risk, 0.87; 95% CI, 0.75 to 1.02) and the as-
treated population (relative risk, 0.90; 95% CI, 
0.78 to 1.03). Predefined subgroup analyses re-
vealed consistency of the results across all sub-
groups (Fig. S1 in the Supplementary Appendix).
Events leading to renal-replacement therapy 
occurred only within the first 30 days, with no 
further events recorded between 30 days and 1 year 
of follow-up. Such an event occurred in 11.6% of 
the patients in the culprit-lesion-only PCI group 
and in 16.4% in the multivessel PCI group (rela-
tive risk, 0.71; 95% CI, 0.49 to 1.03) (Table 3). 
Recurrent myocardial infarction occurred in 
1.7% of the patients in the culprit-lesion-only 
PCI group and in 2.1% in the multivessel PCI 
group (relative risk, 0.85; 95% CI, 0.29 to 2.50), 
and the composite of death or recurrent infarc-
tion was observed in 50.9% and 58.4%, respec-
tively (relative risk, 0.87; 95% CI, 0.76 to 1.00) 
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(Table 3, and Fig. S2 in the Supplementary Ap-
pendix).
Repeat revascularization was performed more 
often with the culprit-lesion-only PCI strategy 
than with the multivessel PCI strategy (in 32.3% 
of the patients vs. 9.4%; relative risk, 3.44; 95% 
CI, 2.39 to 4.95) (Table 3, and Fig. S3 in the 
Supplementary Appendix). Although there were 
Figure 1. Screening, Randomization, Treatment, and Follow-up at 30 Days and at 1 Year in the Intention-to-Treat 
 Population.
CABG denotes coronary-artery bypass grafting, and PCI percutaneous coronary intervention.
706 Underwent randomization
1075 Patients with acute myocardial infarction
and cardiogenic shock were screened
369 Were excluded
184 Had single-vessel coronary artery disease
69 Did not provide informed consent
53 Had undergone resuscitation for >30 min
16 Had severe renal insufficiency at baseline
12 Were participating in another trial
11 Had onset of shock >12 hr earlier
8 Had indication for CABG or did not have
planned PCI
5 Had concomitant severe disease
associated with a life expectancy of <6 mo
3 Were >90 yr old
2 Did not have intrinsic heart action
5 Had other reasons
1 Had mechanical complication 
351 Were assigned to culprit-lesion-only PCI
355 Were assigned to immediate
multivessel PCI
344 Provided full informed consent 342 Provided full informed consent
301 Underwent culprit-lesion-only PCI
43 Underwent immediate multivessel PCI
(60 Underwent staged PCI, 1 underwent
staged CABG, and 13 underwent urgent PCI)
310 Underwent immediate multivessel PCI
32 Underwent culprit-lesion-only PCI
(8 Underwent staged PCI, and 5 underwent
urgent PCI)
344 Had ≥30 days of follow-up
341 Had ≥30 days of follow-up
1 Was lost to follow-up
344 Were included in primary analysis 341 Were included in primary analysis
343 Had 1 yr of follow-up
1 Was lost to follow-up between
30 days and 6 mo
341 Had 1 yr of follow-up
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Characteristic
Culprit-Lesion-Only  
PCI Group 
(N = 344)
Multivessel  
PCI Group 
(N = 342)
Age — yr
Median 70 70
Interquartile range 60–78 60–77
Male sex — no./total no. (%) 257/343 (74.9) 267/342 (78.1)
Body-mass index†
Median 26.6 26.7
Interquartile range 24.2–29.4 24.7–29.4
Cardiovascular risk factors — no./total no. (%)
Current smoking 85/334 (25.4) 89/325 (27.4)
Hypertension 200/339 (59.0) 206/335 (61.5)
Hypercholesterolemia 112/338 (33.1) 116/333 (34.8)
Diabetes mellitus 102/337 (30.3) 116/335 (34.6)
Previous myocardial infarction — no./total no. (%) 60/339 (17.7) 53/335 (15.8)
Previous stroke — no./total no. (%) 29/341 (8.5) 20/336 (6.0)
Known peripheral artery disease — no./total no. (%) 43/341 (12.6) 37/337 (11.0)
Previous PCI — no./total no. (%) 64/339 (18.9) 63/335 (18.8)
Previous coronary-artery bypass grafting — no./total no. (%) 20/341 (5.9) 13/337 (3.9)
Resuscitation before randomization — no./total no. (%) 177/341 (51.9) 189/342 (55.3)
ST-segment elevation myocardial infarction — no./total no. (%) 206/335 (61.5) 209/330 (63.3)
Systolic blood pressure — mm Hg
Median 100 100
Interquartile range 83–120 85–130
Diastolic blood pressure — mm Hg
Median 60 61
Interquartile range 50–80 50–80
Mean blood pressure — mm Hg
Median 76 76
Interquartile range 63–92 63–93
Use of catecholamine — no./total no. (%) 304/344 (88.4) 309/339 (91.2)
Creatinine — mg/dl‡
Median 1.17 1.20
Interquartile range 0.90–1.66 0.90–1.68
Creatinine clearance — ml/min
Median 64 66
Interquartile range 42–95 43–93
No. of affected vessels — no./total no. (%)
1 3/343 (0.9) 2/342 (0.6)
2 122/343 (35.6) 124/342 (36.3)
3 218/343 (63.6) 216/342 (63.2)
Table 1. Characteristics of the Patients at Baseline.*
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few cases of rehospitalization for congestive heart 
failure, the rate was higher in the culprit-lesion-
only PCI group than in the multivessel PCI group 
(5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 
13.04) (Table 3, and Fig. S4 in the Supplemen-
tary Appendix).
The rate of the composite of death, recurrent 
infarction, or rehospitalization for heart failure 
did not differ significantly between the two 
groups (Table 3, and Fig. S5 in the Supplemen-
tary Appendix). In addition, the rates for safety 
end points did not differ significantly between 
the two groups (Table 3). The original primary 
end point of a composite of death or renal- 
replacement therapy was evaluated in a post hoc 
analysis at 1 year; an end-point event occurred in 
52.0% of the patients in the culprit-lesion-only 
PCI group and in 59.5% in the multivessel PCI 
group (relative risk, 0.87; 95% CI, 0.76 to 0.99) 
(Table 3, and Fig. S6 in the Supplementary Ap-
pendix).
EQ-5D values were obtained for 286 of 
the 317 patients who survived. Results on the 
quality-of-life assessment, including the visual-
analogue scale, at 6 months and at 1 year did 
not differ significantly between the two 
groups (Figs. S7 and S8 in the Supplementary 
Appendix).
Discussion
This multicenter, randomized trial compared 
culprit-lesion-only PCI (with the option of staged 
revascularization) with immediate multivessel 
PCI in patients with acute myocardial infarction, 
cardiogenic shock, and multivessel coronary ar-
tery disease. We previously reported that the risk 
of a composite of death from any cause or renal-
replacement therapy was lower with culprit-le-
sion-only PCI than with multivessel PCI in the 
30-day analysis of this trial. In the analysis re-
ported here, we found that mortality did not dif-
fer significantly between the two groups at 1 year. 
However, the rates of rehospitalization for heart 
failure and repeat revascularization were higher 
in the culprit-lesion-only PCI group than the 
multivessel PCI group at 1 year.
The major randomized trials for cardiogenic 
shock showed that death in patients with cardio-
genic shock was mainly confined to the first 30 
days, with mortality during that period ranging 
from 39.7 to 46.7%, depending on the cohorts of 
patients included in the trial, the revasculariza-
tion strategy, and the standard method for re-
vascularization during that time.2,18,19 Mortality 
between 30 days and 1 year was 6.6% in the 
Should We Emergently Revascularize Occluded 
Characteristic
Culprit-Lesion-Only  
PCI Group 
(N = 344)
Multivessel  
PCI Group 
(N = 342)
Vessel related to the infarction — no./total no. (%)
Left anterior descending artery 132/343 (38.5) 156/342 (45.6)
Left circumflex artery 76/343 (22.2) 70/342 (20.5)
Right coronary artery 102/343 (29.7) 89/342 (26.0)
Left main artery 31/343 (9.0) 22/342 (6.4)
Bypass graft 2/343 (0.6) 5/342 (1.5)
≥1 Chronic total occlusion — no./total no. (%) 77/344 (22.4) 82/342 (24.0)
Left ventricular ejection fraction — %
Median 33 30
Interquartile range 25–40 21–40
*  There were no significant differences between the two groups in baseline characteristics. PCI denotes percutaneous 
coronary intervention.
†  Body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
Table 1. (Continued.)
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Variable
Culprit-Lesion-Only  
PCI Group 
(N = 344)
Multivessel  
PCI Group 
(N = 342) P Value
Arterial access — no./total no. (%)
Femoral 287/343 (83.7) 277/342 (81.0) 0.36
Radial 61/343 (17.8) 66/342 (19.3) 0.61
Brachial 2/343 (0.6) 1/342 (0.3) >0.99
Stent in culprit lesion — no./total no. (%)
Any 326/343 (95.0) 324/342 (94.7) 0.86
Bare metal 20/326 (6.1) 17/324 (5.2) 0.63
Drug eluting 305/326 (93.6) 308/324 (95.1) 0.41
Bioresorbable scaffold in culprit lesion — no./total no. (%) 2/326 (0.6) 3/324 (0.9) 0.69
TIMI grade for blood flow — no./total no. (%)*
Before PCI of culprit lesion 0.49
0 189/339 (55.8) 178/337 (52.8)
I 37/339 (10.9) 45/337 (13.4)
II 56/339 (16.5) 50/337 (14.8)
III 57/339 (16.8) 64/337 (19.0)
After PCI of culprit lesion 0.46
0 13/342 (3.8) 16/338 (4.7)
I 12/342 (3.5) 8/338 (2.4)
II 28/342 (8.2) 21/338 (6.2)
III 289/342 (84.5) 293/338 (86.7)
Immediate PCI of nonculprit lesions — no./total no. (%) 43/344 (12.5) 310/342 (90.6) <0.001
Immediate complete revascularization achieved — no./total no. (%) 26/344 (7.6) 277/342 (81.0) <0.001
Total dose of contrast material — ml <0.001
Median 190 250
Interquartile range 140–25 200–350
Total duration of fluoroscopy — min <0.001
Median 13 19
Interquartile range 7–20 12–29
Staged PCI of nonculprit lesions within 30 days — no./total no. (%) 60/344 (17.4) 8/341 (2.3) <0.001
Staged coronary-artery bypass grafting within 30 days — no./total no. (%) 1/344 (0.3)    0/341 (0) >0.99
Mechanical circulatory support — no./total no. (%) 99/344 (28.8) 95/342 (27.8) 0.77
Mechanical ventilation — no./total no. (%) 273/344 (79.4) 282/339 (83.2) 0.20
Subsequent medications in patients who survived until hospital discharge  
— no./total no. (%)
Statin 184/195 (94.4) 152/165 (92.1) 0.40
Beta-blocker 181/195 (92.8) 148/165 (89.7) 0.29
Angiotensin-converting–enzyme inhibitor or angiotensin II type 1 receptor 
antagonist
176/195 (90.3) 140/165 (84.8) 0.12
Aspirin 191/195 (97.9) 163/165 (98.8) 0.54
Clopidogrel 89/195 (45.6) 73/165 (44.2) 0.79
Prasugrel 67/195 (34.4) 56/165 (33.9) 0.93
Ticagrelor 78/195 (40.0) 65/165 (39.4) 0.91
*  Thrombolysis in Myocardial Infarction (TIMI) grades for blood flow range from 0 to III, with higher grades indicating better flow. TIMI grades 
were reported by the investigator.
Table 2. Procedural Characteristics.
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Coronaries for Cardiogenic Shock (SHOCK) trial 
and 12.3% in the Intraaortic Balloon Pump in 
Cardiogenic Shock II (IABP-SHOCK II) trial.20,21 
These rates are similar to the 6.6% mortality 
between 30 days and 1 year that was reported in 
this trial. The results of the landmark analysis 
showed a benefit of culprit-lesion-only PCI over 
multivessel PCI with respect to short-term mor-
tality, and there was no statistical difference 
between the two groups in mortality thereafter. 
These findings do not support the hypothesis 
that immediate multivessel PCI is associated 
with a higher short-term risk of death than cul-
prit-lesion-only PCI but with a diminished risk 
during the longer-term course.22
The rate of rehospitalization for heart failure 
was higher in the culprit-lesion-only PCI group 
than in the multivessel PCI group, although the 
rates were low in both groups and the absolute 
difference in risk between the two groups was 
small. It is possible that this finding could be 
related to the higher rate of complete revascular-
ization in the multivessel PCI group than in the 
culprit-lesion-only PCI group, with complete re-
vascularization leading to subsequent improved 
ventricular function and a lower subsequent in-
cidence of heart failure. However, this interpre-
tation is only speculative, since, to our knowl-
edge, no randomized trials have addressed this 
issue and data on ventricular function were not 
obtained in this trial. The higher rate of rehos-
pitalization for heart failure in the culprit-lesion-
only PCI group could also be a consequence of 
competing risks. Patients with cardiogenic shock 
are at an extreme risk for death, and if they die 
early, they therefore do not survive long enough 
for heart failure to develop in the longer-term 
course. Accordingly, because culprit-lesion-only 
PCI has shown a benefit over multivessel PCI 
with respect to short-term survival, the risk of 
Outcome
Culprit-Lesion-Only  
PCI Group 
(N = 344)
Multivessel  
PCI Group 
(N = 341)
Relative Risk  
(95% CI)
no. (%)
Death from any cause† 172 (50.0) 194 (56.9) 0.88 (0.76–1.01)
Renal-replacement therapy‡ 40 (11.6) 56 (16.4) 0.71 (0.49–1.03)
Recurrent myocardial infarction 6 (1.7) 7 (2.1) 0.85 (0.29–2.50)
Death or recurrent infarction 175 (50.9) 199 (58.4) 0.87 (0.76–1.00)
Rehospitalization for congestive heart failure 18 (5.2) 4 (1.2) 4.46 (1.53–13.04)
Death, recurrent infarction, or rehospitalization  
for heart failure
190 (55.2) 203 (59.5) 0.87 (0.93–1.06)
Repeat revascularization
Any 111 (32.3) 32 (9.4) 3.44 (2.39–4.95)
PCI 107 (31.1) 29 (8.5) 3.66 (2.50–5.36)
Coronary-artery bypass grafting 4 (1.2) 3 (0.9) 1.32 (0.30–5.86)
Death or renal-replacement therapy 179 (52.0) 203 (59.5) 0.87 (0.76–0.99)
Stroke 15 (4.4) 14 (4.1) 1.06 (0.52–2.17)
Bleeding
Any 75 (21.8) 86 (25.2) 0.86 (0.66–1.13)
BARC type 2, 3, or 5§ 65 (18.9) 79 (23.2) 0.82 (0.61–1.09)
*  Confidence intervals were not adjusted for multiple comparisons, and clinical inferences may not be reproducible. Results 
for clinical end points that were analyzed only for patients who survived are shown in Table S2 in the Supplementary 
Appendix.
†  Causes of death are shown in Table S1 in the Supplementary Appendix.
‡  Renal-replacement therapy was defined as any treatment that included dialysis, hemofiltration, or hemodiafiltration.
§  On the Bleeding Academic Research Consortium (BARC) scale, type 2 indicates any overt, actionable sign of bleeding; 
type 3, bleeding with a decrease in the hemoglobin level of more than 3 g per deciliter, any transfusion, cardiac tam-
ponade, or intracranial or ocular involvement; and type 5, fatal bleeding.
Table 3. Clinical and Safety Outcomes at 1 Year.*
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heart failure within the first year may be higher 
with culprit-lesion-only PCI than with multives-
sel PCI.
In previous studies involving patients with acute 
myocardial infarction who did not have cardio-
genic shock, the differences in outcomes between 
those who underwent culprit-lesion-only PCI and 
those who underwent immediate multivessel or 
early staged PCI were driven mainly by a differ-
ence in the rate of repeat revascularization and 
not by differences in rates of hard end points, 
such as death or recurrent infarction. Among 
patients who have cardiogenic shock, the short-
term risks that are associated with longer proce-
dure times, more complex initial interventions, 
and higher doses of contrast material seem to 
outweigh any potential benefits associated with 
reducing the subsequent risk of repeat revascu-
larization. In this trial, after 1 year, 32.3% of the 
patients in the culprit-lesion-only PCI group had 
undergone staged or urgent repeat revascular-
ization. This rate is higher than rates seen in 
trials of revascularization strategies in patients 
who did not have cardiogenic shock, which range 
from 8.2 to 17.4% at 1 year of follow-up.23-26 The 
higher rate of repeat revascularization in the 
culprit-lesion-only PCI group in this trial may be 
related to the extent of coronary artery disease, 
the presence of impaired left ventricular func-
tion, and the severity of illness in patients with 
cardiogenic shock, as well as to the trial design. 
It is unclear whether an even higher rate of re-
vascularization of nonculprit lesions could have 
prevented rehospitalizations for heart failure.
This trial has several limitations. First, all the 
end points in the 1-year analysis are exploratory 
because the trial was powered for the 30-day 
analysis of the primary composite end point. 
Second, blinding was not possible owing to the 
nature of the intervention performed. Manage-
ment of cardiogenic shock involves a complex 
series of clinical decisions, and residual bias in 
the course of such management cannot be ruled 
out. Third, the results of serial echocardiogra-
phy to assess cardiac function were not avail-
able, and such results would have allowed us to 
explore potential underlying causes of the initial 
higher mortality with multivessel PCI and the 
subsequent higher rate of rehospitalization for 
heart failure with culprit-lesion-only PCI.
In conclusion, this multicenter, randomized 
trial compared culprit-lesion-only PCI (with the 
option of staged revascularization) with imme-
diate multivessel PCI in patients with acute 
myocardial infarction, cardiogenic shock, and 
multivessel coronary artery disease. At 30 days, 
the risk of a composite of death from any cause 
or renal-replacement therapy was significantly 
lower with culprit-lesion-only PCI than with mul-
tivessel PCI. At 1 year, mortality did not differ 
significantly between the two groups. However, 
Figure 2. Time-to-Event and Landmark Analyses for Death from Any Cause 
through 1 Year.
Panel A shows Kaplan–Meier estimates of the rate of death from any cause 
through 1 year. Panel B shows the results of a landmark analysis of the rate 
of death from any cause through 30 days, as well as the rate between 30 days 
and 1 year.
Pa
tie
nt
s 
W
ho
 D
ie
d 
fr
om
 A
ny
 C
au
se
 (%
)
100
80
90
70
60
40
30
10
0
50
20
0 60 120 180 240 300 360 420
420
Days since Randomization
B Landmark Analysis
A Time-to-Event Analysis
Relative risk, 0.88 (95% CI, 0.76–1.01)
Relative risk, 1.08
(95% CI, 0.60–1.93)
No. at Risk
Multivessel PCI
Culprit-lesion-only
PCI
341
344
161
186
160
181
156
178
152
174
149
172
131
147
Multivessel PCI
Culprit-lesion-only PCI
Pa
tie
nt
s 
W
ho
 D
ie
d 
fr
om
 A
ny
 C
au
se
 (%
)
100
80
90
70
60
40
30
10
0
50
20
0 60 120 180 240 300 360
Days since Randomization
Relative risk, 0.84
(95% CI, 0.72–0.98)
No. at Risk
Multivessel PCI
Culprit-lesion-only PCI
161
186
30
165
195
160
181
156
178
152
174
149
172
131
147
Multivessel PCI
Culprit-lesion-only PCI
The New England Journal of Medicine 
Downloaded from nejm.org at E-Library Insel on January 21, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;18 nejm.org November 1, 2018 1709
PCI Str ategies in Cardiogenic Shock
the incidence of rehospitalization for heart fail-
ure was higher and repeat revascularization was 
more frequent with culprit-lesion-only PCI than 
with multivessel PCI at 1 year.
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